Download the FREE ebook "Beating Myeloma: If I Knew Then What I Know Now" and arm yourself with the information about autologous stem cell transplantation, treatment options, and side effects that I wish I had known about when I began treatment.
The study linked and excerpted below documents how an elavated c-reactive protein level indicates a worse outcome for the myeloma patient who waits 12 months or more after his/her initial diagnosis to undergo an autlogous stem cell transplant.
Waiting longer to undergo ASCT does not have to mean that you don’t treat your health. How about undergoing therapies to reduce your CRP? How about undergoing evidence-based, anti-MM nutrition, supplementation and detoxification?
My name is David Emerson. I am a long-term MM survivor and MM Cancer Coach. Please watch my free webinar to learn more about the MM Cancer Coaching program that I researched and designed based on my own long-term MM experience.
Scroll down the page, post a question or comment if you’d like to learn more about evidence-based non-conventional MM therapies.
“C-reactive protein (CRP) is an annular (ring-shaped), pentameric protein found in blood plasma, whose levels rise in response to inflammation. It is an acute-phase protein of hepatic origin that increases following interleukin-6 secretion by macrophages and T cells…
“Interestingly, higher levels of C-reactive Protein are indicative of worse overall survival for Arkansas total therapy patients and those treated with the chemotherapy anthracycline or thalidomide-based induction treatments. However, a decrease of C-reactive Protein for smoldering myeloma patients actually shows better progression-free and overall survival…”
“We analyzed 1111 MM patients who underwent ASCT at Mayo Clinic from 2007 to 2015…
Elevated CRP (> upper normal limit (8 mg/L)) was seen in 14% and 22% of patients undergoing early and delayed ASCT, respectively (P=0.003).
There was no correlation of CRP with pre-transplant response, bone marrow plasma cell percentage or labeling index. Patients with an elevated CRP had a higher likelihood of having circulating plasma cells prior to ASCT
In the early ASCT cohort, the median overall survival (OS) in patients with normal and elevated CRP was not reached and 91 months respectively.
In the delayed ASCT cohort, the median OS in respective groups were 73 and 30 months respectively, with elevated CRP being an independent prognostic marker on multivariate analysis.
Elevated pre-transplant CRP identifies a high-risk population especially in patients undergoing delayed ASCT and should be incorporated in the pre-transplant evaluation…”